OUR TEAM MEMBERS
Chris Buyse was CFO at ThromboGenics NV from September 2006 until June 2014. He has 30 years of experience in international company finance and in running and establishing best financial practice. He was previously CFO of the Belgian biotechnology company CropDesign. Before this, he was Finance Director of WorldCom/MCI Belux, and was CFO and interim CEO of Keyware Technologies, in addition, he held several financial positions at Suez Lyonnaise des Eaux and Unilever. He is currently serving as an independent Board Member of a few companies, mostly active in life sciences such as Celyad and Inventiva.
Philippe Monteyne holds an M.D. degree trained as a Neurologist and a Ph.D. in Viral Immunology, both at the UCL (Univ. Cathol. de Louvain), followed by a post-doctoral fellowship at Pasteur Institute, Paris. During the last 20 years, he held senior positions in top pharma companies such as SmithKline Beecham, GSK Biologicals (as Head of Global Vaccine Development) and GSK Rare Diseases (Head of Development and Chief Medical Officer) and SANOFI (Vice President R&D France). He is also currently member of different Strategic Advisory Committees. He is also visiting Professor of Neurology at the UCL.
Caroline holds a Ph.D. in Pharmaceutical Sciences at KU Leuven followed by an MBA and an executive master in corporate finance, both from Vlerick Business School. She started her career at UCB taking on various roles ranging from commercial responsibilities (marketing and sales) to business development, portfolio management and R&D strategy. Fascinated by the intersection of research and commercialisation, she then joined Gimv where she focused on early stage biotech and medtech investment opportunities while driving portfolio value as a board member of companies in biotech (Complix) and diagnostics (Multiplicom).
Lawrence Van Helleputte
Lawrence holds a Ph.D. in Biomedical Sciences from the VIB-KU Leuven Centre of Brain & Disease Research. There, he focused on the pathophysiology underlying peripheral neuropathies which contributed to the successful creation of Augustine Therapeutics, a spin-off intended to give clinical answers to devastating neuromuscular and neurodegenerative disorders. After his academic passage, Lawrence made the transition to start-up biotech and worked for more than 3 years as a Senior Scientist at CoBioRes NV, converging the preclinical development of targeted anti-cancer therapies. His tremendous desire to work on the frontline of upcoming technologies and innovations directed him towards Fund+, where he joined the team as Scientific Investment Analyst in the fall of 2021.
Halina Novak holds a Ph.D. in Biological Science from the University of Exeter, UK. She started her career with an industry sponsored postdoctoral fellowship, where she worked on industrial applications of enzymes for Unilever, which resulted in a number of granted patents. Halina went on to work at VIB, at the intersection between industry and academia where she held several positions in Technology and Innovation. Notably, she headed the Tech Watch Program and Technology Innovation Lab, where unique strategies were developed to identify, evaluate and implement breakthrough life science technologies. During her 8 years at VIB, she managed a portfolio of projects with companies developing breakthrough technologies, which resulted in many successful investments in cutting edge tools that have since revolutionised the Life Sciences.
Diane De Wyngaert
Diane holds a bachelor degree in informatics. She worked as administrative assistant and bookkeeper for several companies such as ADB (Siemens), VIB and Life Sciences Research Partners (still currently).